El interés en corto de Alaunos Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Alaunos Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Alaunos Therapeutics (NASDAQ:TCRT) Bolsa, Informe de interés en corto

Alaunos Therapeutics

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics Inc

Earnings

News

MGRM

Monogram Technologies Q3 EPS $(0.16) Down From $(0.03) YoY

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Buy and maintains $39 price target.

Price Target

Analyst Ratings

FDMT

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $39 Price Target

Snap Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) Snapchat is introducing a new real-time location sharing feature designed for family members, allowing users to share their live<a href="https://www.benzinga.com/topic/consumer-tech"> locations with others. </a>
The update will roll out in the coming weeks, alongside new privacy and location tools. This feature is aimed at improving user safety, especially for parents tracking their teens' whereabouts, the company <a href="https://parents.snapchat.com/parental-controls">announced. </a>
See Also: <a href="https://www.benzinga.com/news/24/10/41618021/snap-touts-new-ad-formats-and-simple-snapchat-10m-users-trial-growth-driving-feature">Snap Touts New Ad Formats And &#8216;Simple Snapchat&#8217; — 10M Users Trial Growth-Driving Feature</a>
Once available, the Family Center will include an option for parents to request their child&#8217;s location, and vice versa. The platform will also allow users to view and adjust location-sharing settings, alongside other privacy controls. 
Additionally, Snapchat will enable automatic travel notifications, alerting family members when someone arrives at or leaves specific locations, such as home or school.
<h3 class="wp-block-heading">Snapchat&#8217;s Privacy And Safety Concerns</h3>
While the new features have practical uses, their timing has sparked debate.<a href="https://parents.snapchat.com/parental-controls"> According </a>to The Verge, the app is currently involved in a lawsuit filed by New Mexico&#8217;s attorney general, Raúl Torrez, who claims Snapchat failed to act on warnings about the platform being used to target minors for "sextortion" and other forms of exploitation. 
Torrez has also criticized the app's design, which automatically deletes messages, photos, and videos after a set time, arguing that it complicates efforts to keep users safe.
The company's decision to roll out location sharing in the midst of these legal challenges may lead to additional scrutiny, especially as it relates to the platform's ability to protect its users' privacy. 
In response to these concerns, Snapchat is making location-sharing an opt-in feature, available only to friends and family. Users will also receive prompts to review their privacy settings when adding new connections.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/02/37306324/instagram-is-working-on-a-snapchat-like-friends-map-feature-heres-how-it-works">Instagram Is Working On A Snapchat-like &#8216;Friends Map&#8217; Feature: Here&#8217;s How It Works</a></li>
</ul>
Photo: Diego Thomazini/Shutterstock.com

Social Media

Tech

SNAP

Snapchat Puts Family On The Map With New Real-Time Locator

Florida GOP Senator <a href="https://www.benzinga.com/topic/marco-rubio">Marco Rubio</a> is President-elect <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a>'s <a href="https://www.benzinga.com/24/11/41959835/trump-nominates-marco-rubio-as-secretary-of-state-calls-florida-senator-a-powerful-voice-for-freedom">pick for the role</a> of Secretary of State.
Trump praised Rubio (53) as a "highly respected leader" and a "powerful voice for freedom." But, will he be that open-minded when it comes to cannabis policy reform?
Judging by his earlier stance, what's left for cannabis shareholders and advocates, is hope.
<h3 class="wp-block-heading">Rubio Is Just Not That Into Cannabis</h3>
In a 2022 <a href="https://www.youtube.com/watch?v=63UZT6rEAdQ">interview</a> with a Pensacola TV station, Rubio revealed his reasons for taking a stance against federal cannabis legalization. The concept of cannabis as a "gateway" drug, or one leading users to more dangerous drugs, was one of his main concerns.
&#8220;When you decriminalize something, the message that you&#8217;re basically sending people is it must not be that bad,&#8221; Rubio said, as <a href="https://www.benzinga.com/markets/cannabis/22/04/26666538/marco-rubio-reveals-why-he-opposes-cannabis-legalization">highlighted</a> by Benzinga's <a href="https://www.benzinga.com/author/nina-zdinjak">Nina Zdinjak</a>. &#8220;Now, suddenly, you&#8217;re an 18- or 17-year-old, [and you] say,&nbsp;&#8216;well, I know marijuana, you tell me not to smoke it, but you know what? It can&#8217;t be that bad, because the federal government made it legal.'&#8221;
At the time, Rubio also argued that cannabis bought from illegal sources has been&nbsp;<a href="https://www.benzinga.com/markets/cannabis/19/09/14451540/report-synthetic-marijuana-fentanyl-found-in-cbd-labeled-products">laced with the strong opioid fentanyl</a>, a drug involved in about 30,000 overdose deaths last year.&nbsp;
Read Also: <a href="https://www.benzinga.com/news/global/24/11/41893397/trump-reportedly-considers-marco-rubio-for-secretary-of-state-role-who-shares-similar-stance-for-china-but-says-stock-market-is-not-the-economy">Trump Reportedly Considers Marco Rubio For Secretary Of State Role Who Shares Similar Stance For China, But Says Stock Market &#8216;Is Not The Economy&#8217;</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Asked by the Daily Mail nearly a decade ago whether he ever used cannabis, Rubio answered ambiguously, <a href="https://reason.com/2015/02/04/why-wont-marco-rubio-admit-he-smoked-pot/">reported</a> Reason. 
"I&#8217;ll tell you why I never answer that question,&#8221; he said back in 2014. &#8220;If I tell you that I haven&#8217;t, you won&#8217;t believe me. And if I tell you that I did, then kids will look up to me and say, &#8216;well, I can smoke marijuana because look how he made it.'&#8221;
That&#8217;s because there's "no responsible way to recreationally use" marijuana, according to Rubio, <a href="https://www.huffpost.com/entry/marco-rubio-marijuana_n_5352382">reported</a> HuffPost.
This stance doesn't come as a surprise considering that in 2014 he expressed his support for continued criminal penalties for recreational cannabis use. "I don&#8217;t think legalizing marijuana or even decriminalizing it is the right decision for our country,&#8221; Rubio said as <a href="https://www.tampabay.com/opinion/2024/09/19/better-justice-system-florida-should-legalize-recreational-marijuana-heres-why/">reported</a> by Tampa Bay.
Moreover, during his unsuccessful 2016 presidential campaign, he openly supported cracking down on states that have legalized marijuana and enforcing the law, that prohibits marijuana, <a href="https://www.browardpalmbeach.com/news/marco-rubio-says-hed-crack-down-on-marijuana-if-elected-president-7174851">reported</a> Broward Palm Beach New Times. "I believe the federal government needs to enforce federal law,&#8221; he said at the time.
<h3 class="wp-block-heading">But…</h3>
Interestingly, Rubio also said medical use of cannabis is something he could consider if it is the non-psychoactive type.
In 2016, he reiterated his stance on the recreational use of cannabis, but slightly amended his view on medical marijuana, <a href="https://www.washingtontimes.com/news/2016/feb/11/rubio-no-responsible-way-habitual-marijuana-use/">reported</a> the Washington Times. He said "If there's a medicinal use — if you can go to the FDA and prove that it helps with medicine, that's fine. Then turn it into medicine."
Keeping in mind that Rubio once referred to Trump as "the most vulgar person," one cannot help but wonder whether Rubio will take a U-turn on cannabis. Or is the saying "The fox changes its fur but not its vice," a more probable scenario?
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41950826/kristi-noems-appointment-as-homeland-security-secretary-raises-questions-about-federal-cannabis-policy">Trump&#8217;s Appointment Of Kristi Noem To Homeland Security Chief Raises Questions About Fed Cannabis Policy</a></li>
</ul>

Cannabis

Government

Politics

Trump Says His Secretary Of State Pick Marco Rubio Is 'Powerful Voice For Freedom' – But What About Cannabis?

WIIM

PLTR

Palantir Technologies shares are trading higher after the company announced it will transfer its stock exchange listing over to the Nasdaq.

Trading Ideas

Market Vectors ETF Trust Market Vectors Gold Miners

MSTR

Rydex ETF Trust Rydex S&P Equal Weight ETF

Elliott Investment Management 13F Shows Exited Position In Marathon Petroleum, Previously Holding 7,365,000 Shares; Ishares Biotechnology ETF Put Position, Previously Holding 2,800,000 Shares; Invesco S&P 500 Equal Weight ETF Put Position, Previously Holding 1,925,000 Shares; Vaneck Gold Miners ETF Put Position, Previously Holding 5,000,000 Shares; BHP Group Ltd Call Position, Previously Holding 2,500,000 Shares; MicroStrategy Convertible Note, Previously Holding $27.5 Million In Principal

Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. The company reported quarterly sales of $3.336 million which beat the analyst consensus estimate of $1.520 million by 119.55 percent. This is a 58.86 percent increase over sales of $2.100 million the same period last year.

Earnings Beats

Cue Biopharma Q3 2024 GAAP EPS $(0.17) Beats $(0.19) Estimate, Sales $3.336M Beat $1.520M Estimate

HALO

Evotec shares are trading higher after the company announced it received a proposal to be acquired by Halozyme for approximately $2.1 billion.

HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.28) by 14.06 percent. The company reported quarterly sales of $4.703 million which missed the analyst consensus estimate of $6.250 million by 24.75 percent. This is a 31.51 percent decrease over sales of $6.867 million the same period last year.

Earnings Misses

HOOK

HOOKIPA Pharma Q3 2024 GAAP EPS $(1.10) Beats $(1.28) Estimate, Sales $4.703M Miss $6.250M Estimate

General

Kezar Life Sciences Received A Letter From The Listing Qualifications Staff Of The Nasdaq Notifying The Company That It Has Regained Compliance With Nasdaq Listing Rule 5550(A)(2)

Biotech

Events

SLNO

Soleno Therapeutics Announces Presentation Featuring Diazoxide Choline Extended-Release Tablets In Prader-Willi Syndrome At ESPE 2024

SDRL

Elliott Investment Management 13F Shows Decreased Put Position In Vaneck Oil Services ETF From 1,450,000 To 1,260,000 Shares; Decreased Stake In NRG Energy By 7% From 10,359,000 To 9,668,000 Shares; Decreased Stake In Seadrill Ltd By 9% From 4,050,984 To 3,703,746 Shares; Decreased Stake In XME Put Position By 18% From 5,000,000 To 4,100,000 Shares; Decreased Stake In Ishares QQQ Trust Put Position By 92% From 5,910,000 Shares To 450,000 Shares

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/24/11/b41988748/oklo-publishes-third-quarter-2024-financial-results-and-business-update">nuclear company&#8217;s report</a>.
Q3 Earnings: Oklo reported a third-quarter loss of eight cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The Sam Altman-backed company noted it used $24.9 million of cash in operations year-to-date.
Oklo reported operating losses of $37.4 million since the start of the year. The company said it remains on track to meet its full-year operating loss forecast of $40 to $50 million.
Oklo ended the quarter with $288.5 million in cash, cash equivalents and marketable securities. 
&#8220;We are entering an era of unprecedented energy demand — rivaled perhaps only by initial conversion to electrification over a century ago. The world is now recognizing nuclear's role in powering that future,&#8221; said Jacob DeWitte, co-founder and CEO of Oklo.
&#8220;Momentum is building every week — regulators are modernizing, bipartisan support is growing and some of the most influential companies are investing heavily in the space.&#8221;
Don&#8217;t Miss: <a href="https://www.benzinga.com/top-stories/24/11/41915547/trumps-fossil-fuel-push-may-satisfy-ais-soaring-energy-demand-but-what-about-nuclear">Trump&#8217;s Fossil Fuel Push May Satisfy AI&#8217;s Soaring Energy Demand — But What About Nuclear?</a>
Oklo announced earlier this week that it&#8217;s partnering with two major data center providers to deliver up to 750 MW of power. The commitments bring Oklo's customer pipeline up to approximately 2,100 MW.
Oklo also said it plans to submit its combined license application to the U.S. Nuclear Regulatory Commission (NRC) during the first half of 2025.
&#8220;With a site permit and secured fuel, we believe we're poised to be a leader in deploying advanced nuclear by late 2027. As the world experiences an extraordinary transformation driven by AI, the future demands an equally bold solution for energy. We're proud to lead the way,&#8221; DeWitte said. 
Management will hold a call to discuss the quarter with investors and analysts at 4:30 p.m. ET.
OKLO Price Action: <a href="http://benzinga.com/quote/oklo" target="_blank" rel="noreferrer noopener">Oklo shares</a> were down 5.74% in after hours, trading at $22.51 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of Oklo.

After-Hours Center

Movers

OKLO

Sam Altman-Backed Oklo Reports Q3 Earnings: 'Momentum Is Building Every Week'

TFFP

Trading Halt: Halt status updated at 4:40:00 PM ET: Quotation Resumption: News and Resumption Times

Flexible Solutions Intl (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSI#AMEX">FSI</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 183.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $9.31 million which missed the analyst consensus estimate of $10.88 million by 14.38 percent. This is a 6.81 percent increase over sales of $8.72 million the same period last year.

Flexible Solutions Intl Q3 EPS $0.05 Misses $0.06 Estimate, Sales $9.31M Miss $10.88M Estimate

Federal Reserve Chair Jerome Powell indicated Thursday the remarkable strength of the U.S. economy is not sending any signals that policymakers &#8220;need to be in a <a href="https://www.benzinga.com/topic/interest-rates">hurry to lower rates.&#8221;</a>
Powell&#8217;s remarks came at an event organized by the Dallas Regional Chamber on Thursday, just a week after his press conference following the November Federal Reserve meeting.
&#8220;Inflation is running much closer to our 2% longer-run goal, but it is not there yet. We are committed to finishing the job,&#8221; Powell said. 
The Fed chair hinted that interest rates may be moving &#8220;to a more neutral setting,&#8221; but stressed that &#8220;the path for getting there is not preset.&#8221;
<h3 class="wp-block-heading">Powell Hints At Economic Strength, Warns About Risk Of Tariff Retaliations</h3>
Powell described the U.S. economy&#8217;s recent performance as &#8220;by far the best of any major economy in the world.&#8221; He attributed this strength in part to increased productivity.
&#8220;Productivity has grown faster over the past five years than its pace in the two decades before the pandemic, increasing the productive capacity of the economy and allowing rapid economic growth without overheating,&#8221; he said.
This resilience in the economy, according to Powell, gives the Federal Reserve the flexibility to &#8220;approach our decisions carefully,&#8221; though he underscored that the future path of interest rates would depend on how incoming data and economic forecasts evolve.
Powell expressed confidence that, with careful adjustments to the Fed's policy stance, the strength of both the economy and the labor market could be preserved, while inflation trends back down to the Fed&#8217;s 2% target.
Regarding the labor market, Powell downplayed the significance of the October jobs report, noting it was influenced by temporary factors such as hurricanes and labor strikes.
He also indicated no urgency to change Fed policy in response to potential shifts in fiscal policy under the new Trump&#8217;s administration.
&#8220;It takes quite a long time to get a bill through Congress. We have time to make assessments about what the net effects of policy changes will be on the economy before we work with policy,&#8221; he said.
Powell reiterated his concern over the U.S. fiscal trajectory, calling it &#8220;unsustainable.&#8221; 
&#8220;We have a very large deficit at a time when we&#8217;re at full employment,&#8221; Powell said, adding that he and recommended addressing it &#8220;sooner rather than later.&#8221;
When asked about the impact of higher trade tariffs on monetary policy, Powell was cautious but said scenarios involving retaliatory measures from other countries would require close monitoring by the Fed.
<h3 class="wp-block-heading">Market Reactions</h3>
Powell's cautious remarks about the path for interest rates led to a sharp repricing of December rate cut expectations. 
According to the CME FedWatch tool, the probability of a 25-basis-point rate cut in December has dropped, with Fed futures now indicating a 62% chance, down from prior estimates of nearly 80%.
In response, the U.S. dollar rallied, extending its winning streak to five sessions. Treasury yields also reversed course, with significant gains across the curve as investors adjusted their rate expectations. The yield on the two-year Treasury note, which is particularly sensitive to Fed policy shifts, jumped 6 basis points to 4.34%.
Equity markets reacted negatively to Powell's tone. Major U.S. indices turned lower, with the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), down 0.7%. The tech-heavy Nasdaq-100, represented by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), slipped 0.8%.
Small-cap stocks suffered the most, with the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) dropping 1.3%, signaling broader risk aversion among investors. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Dallas Regional Chamber: Global Perspectives with Federal Reserve Chair Jerome Powell" width="500" height="281" src="https://www.youtube.com/embed/vhbdv8jXmvQ?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">Producer Inflation Rises More Than Expected In October: Should Traders Rethink Interest Rate Cut Path?</a></li>
</ul>
Photo: Jerome Powell at the Nov. 7 FOMC press conference. Photo courtesy of the Federal Reserve.

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Markets

ETFs

Powell: With Strong US Economy, Fed Has 'No Need To Be In A Hurry To Lower Rates'

XPON

Expion360 Q3 EPS $(24.55) Up From $(26.25) YoY; Revenue $1.389M Down From $1.890M YoY

DBGI

Digital Brands Group Q3 EPS $(1.63), Sales $2.44M Down From $3.26M YoY

ZURA

Zura Bio Announces Submission Of Protocol To FDA For Phase 2 Study Of Tibulizumab In Adults With Systemic Sclerosis

Offerings

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Files For Offer And Resale By Selling Stockholders Of Up To 1,577,829 Shares Of Common Stock

The market has been high on Alaunos Therapeutics Inc (TCRT)  stock recently. TCRT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Alaunos Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TCRT!See Full TCRT ReportWhat is Stock Senti

Is Alaunos Therapeutics Inc (TCRT) a Stock to Watch After Losing -8.86% This Week?

Alaunos Therapeutics (TCRT) has released an update. Alaunos Therapeutics, Inc. has successfully regained compliance with Nasdaq's minimum $1.00 bid...

Alaunos Therapeutics Regains Nasdaq Listing Compliance

Alaunos Therapeutics (TCRT) has released an update. Michael Wong resigned as Vice President, Finance of Alaunos Therapeutics, and Ferdinand Groenew...

Alaunos Therapeutics Announces Executive Financial Leadership Changes

Wall Street is positive on Alaunos Therapeutics Inc (TCRT). On average, analysts give Alaunos Therapeutics Inc a Hold rating. The average price target is $2.998, which means analysts expect the stock to climb by 74.30% over the next twelve months.That average ranking earns Alaunos Therapeutics Inc an Analyst Rating of 5, w

How Does Alaunos Therapeutics Inc (TCRT) Stock Rank on Wall Street Friday?

Overall market sentiment has been high on Alaunos Therapeutics Inc (TCRT)  stock lately. TCRT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Alaunos Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TCRT!See Full TCRT ReportWh

Do Traders Think Alaunos Therapeutics Inc (TCRT) Can Keep Climbing Tuesday?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Alaunos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/">TCRT</a>) just reported results for the fourth quarter of 2023.<ul><li>Alaunos Therapeutics reported earnings per share of -55 cents. This was below the analyst estimate for EPS of -45 cents.</li><li>The company reported revenue of $1,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/tcrt-stock-earnings-alaunos-therapeutics-for-q4-of-2023/">TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Alaunos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/">TCRT</a>) just reported results for the first quarter of 2024.<ul><li>Alaunos Therapeutics reported earnings per share of -11 cents.</li><li>The company reported revenue of $1,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/tcrt-stock-earnings-alaunos-therapeutics-for-q1-of-2024/">TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Alaunos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/">TCRT</a>) just reported results for the second quarter of 2024.<ul><li>Alaunos Therapeutics reported earnings per share of -71 cents.</li><li>The company reported revenue of $4,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tcrt-stock-earnings-alaunos-therapeutics-for-q2-of-2024/">TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024

The latest announcement is out from Alaunos Therapeutics ( ($TCRT) ). Alaunos Therapeutics, Inc. has decided to terminate its amended licensing agr...

Comments

Alaunos Therapeutics

Interés en corto

Alaunos Therapeutics (NASDAQ:TCRT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL